INTS News & Events

Intensity Therapeutics announced that the board of directors of the Company approved a 1-for-25 reverse stock split of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on October 22, 2025. The Reverse Split will legally take effect on February 18. The Company's common stock will open for trading under a new CUSIP number 45828J 202 on The Nasdaq Capital Market on February 19, 2026, on a split-adjusted basis under the current ticker symbol "INTS." The Reverse Split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

The company plans to maintain a disciplined operating approach in 2026 and will seek to opportunistically raise additional capital during 2026 to reinitiate patient enrollment and site activations in the INVICIBLE-3 Study, and to potentially initiate a new Phase 3 Breast Cancer Study. The company raised over $20M in gross proceeds during 2025 through two public offerings, one registered direct offering, and ATM issuances. These successful capital-raising efforts strengthened Intensity's balance sheet and extended its current operating runway into the second quarter of 2027, providing flexibility to advance certain clinical programs without near-term financing pressure. The company is continuing to pursue discussions with potential pharmaceutical partners to potentially accelerate the development and commercialization of its new drug.

Intensity Therapeutics announces it will present two posters at the San Antonio Breast Cancer Symposium, SABCS, in San Antonio, TX being held at the Henry B. Gonzalez Convention Center. Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable safety: 50% fewer grade 3 or higher Adverse Events were observed in the INT230-6 cohort compared to the Standard of Care neoadjuvant chemotherapy alone cohort. Poster PS4-10-15 Describes An Overview of a Potential Phase 3 Clinical Study Design with INT230-6 plus standard of care with and without the toxic anthracycline, doxorubicin